Found: 49
Select item for more details and to access through your institution.
Imatinib dose reduction in patients with chronic myeloid leukemia in sustained deep molecular response.
- Published in:
- 2017
- By:
- Publication type:
- journal article
Sustained antiviral response against in vitro HIV-1 infection in peripheral blood mononuclear cells from people with chronic myeloid leukemia treated with ponatinib.
- Published in:
- Frontiers in Pharmacology, 2024, p. 1, doi. 10.3389/fphar.2024.1426974
- By:
- Publication type:
- Article
Outcomes of chronic myeloid leukemia patients after therapeutic failure to conventional tyrosine kinase inhibitors and asciminib.
- Published in:
- Annals of Hematology, 2024, v. 103, n. 11, p. 4537, doi. 10.1007/s00277-024-05906-6
- By:
- Publication type:
- Article
Correction to: An analysis of the kinetics of molecular response during the first trimester of treatment with nilotinib in newly diagnosed chronic myeloid leukemia patients in chronic phase.
- Published in:
- 2018
- By:
- Publication type:
- Erratum
An analysis of the kinetics of molecular response during the first trimester of treatment with nilotinib in newly diagnosed chronic myeloid leukemia patients in chronic phase.
- Published in:
- Journal of Cancer Research & Clinical Oncology, 2017, v. 143, n. 10, p. 2059, doi. 10.1007/s00432-017-2445-z
- By:
- Publication type:
- Article
Assessment of the potential value of plasma Torque Teno virus DNA load monitoring to predict cytomegalovirus DNAemia in patients with hematological malignancies treated with small molecule inhibitors: A proof‐of‐concept study.
- Published in:
- Journal of Medical Virology, 2023, v. 95, n. 7, p. 1, doi. 10.1002/jmv.28933
- By:
- Publication type:
- Article
Identification of Immunological Parameters as Predictive Biomarkers of Relapse in Patients with Chronic Myeloid Leukemia on Treatment-Free Remission.
- Published in:
- Journal of Clinical Medicine, 2021, v. 10, n. 1, p. 42, doi. 10.3390/jcm10010042
- By:
- Publication type:
- Article
Current Treatment Options for Chronic Myeloid Leukemia Patients Failing Second-Generation Tyrosine Kinase Inhibitors.
- Published in:
- Journal of Clinical Medicine, 2020, v. 9, n. 7, p. 2251, doi. 10.3390/jcm9072251
- By:
- Publication type:
- Article
Treatment‐free remission after dasatinib in patients with chronic myeloid leukaemia in chronic phase with deep molecular response: Final 5‐year analysis of DASFREE.
- Published in:
- British Journal of Haematology, 2023, v. 202, n. 5, p. 942, doi. 10.1111/bjh.18883
- By:
- Publication type:
- Article
Immunobiology of cytomegalovirus infection in patients with haematological malignancies undergoing treatment with small molecule inhibitors.
- Published in:
- British Journal of Haematology, 2023, v. 200, n. 6, p. e58, doi. 10.1111/bjh.18655
- By:
- Publication type:
- Article
Cytoreductive treatment in patients with CALR‐mutated essential thrombocythaemia: a study comparing indications and efficacy among genotypes from the Spanish Registry of Essential Thrombocythaemia.
- Published in:
- British Journal of Haematology, 2021, v. 192, n. 6, p. 988, doi. 10.1111/bjh.16988
- By:
- Publication type:
- Article
Clinical characteristics, prognosis and treatment of myelofibrosis patients with severe thrombocytopenia.
- Published in:
- 2018
- By:
- Publication type:
- Letter to the Editor
Frequency and prognostic value of resistance/intolerance to hydroxycarbamide in 890 patients with polycythaemia vera.
- Published in:
- British Journal of Haematology, 2016, v. 172, n. 5, p. 786, doi. 10.1111/bjh.13886
- By:
- Publication type:
- Article
The prognostic impact of non‐driver gene mutations and variant allele frequency in primary myelofibrosis.
- Published in:
- American Journal of Hematology, 2024, v. 99, n. 4, p. 755, doi. 10.1002/ajh.27203
- By:
- Publication type:
- Article
Allogeneic hematopoietic cell transplantation in older myelofibrosis patients: A study of the chronic malignancies working party of EBMT and the Spanish Myelofibrosis Registry.
- Published in:
- American Journal of Hematology, 2021, v. 96, n. 10, p. 1186, doi. 10.1002/ajh.26279
- By:
- Publication type:
- Article
Hemolytic crisis due to Covid‐19 vaccination in a woman with cold agglutinin disease.
- Published in:
- American Journal of Hematology, 2021, v. 96, n. 8, p. E288, doi. 10.1002/ajh.26214
- By:
- Publication type:
- Article
Impaired Cytotoxic Response in PBMCs From Patients With COVID-19 Admitted to the ICU: Biomarkers to Predict Disease Severity.
- Published in:
- Frontiers in Pharmacology, 2021, v. 11, p. 1, doi. 10.3389/fimmu.2021.665329
- By:
- Publication type:
- Article
Impact of the COVID-19 pandemic on the diagnosis and treatment of onco-hematologic patients: a discussion paper.
- Published in:
- Revista Española de Quimioterapia, 2023, v. 36, n. 1, p. 1, doi. 10.37201/req/087.2022
- By:
- Publication type:
- Article
Hepatotoxicity as dose-limiting toxicity of the combination of bosutinib and atezolizumab in patients with chronic myeloid leukemia. Results of the ZEROLMC study.
- Published in:
- Annals of Hematology, 2024, v. 103, n. 10, p. 4045, doi. 10.1007/s00277-024-05662-7
- By:
- Publication type:
- Article
Low-risk polycythemia vera treated with phlebotomies: clinical characteristics, hematologic control and complications in 453 patients from the Spanish Registry of Polycythemia Vera.
- Published in:
- 2022
- By:
- Publication type:
- journal article
Natural history of polycythemia vera and essential thrombocythemia presenting with splanchnic vein thrombosis.
- Published in:
- 2020
- By:
- Publication type:
- journal article
Safety and efficacy of bosutinib in fourth-line therapy of chronic myeloid leukemia patients.
- Published in:
- Annals of Hematology, 2019, v. 98, n. 2, p. 321, doi. 10.1007/s00277-018-3507-2
- By:
- Publication type:
- Article
Prognostic risk models for transplant decision-making in myelofibrosis.
- Published in:
- 2018
- By:
- Publication type:
- journal article
Oral anticoagulation to prevent thrombosis recurrence in polycythemia vera and essential thrombocythemia.
- Published in:
- Annals of Hematology, 2015, v. 94, n. 6, p. 911, doi. 10.1007/s00277-015-2330-2
- By:
- Publication type:
- Article
Early Cellular and Humoral Responses Developed in Oncohematological Patients after Vaccination with One Dose against COVID-19.
- Published in:
- Journal of Clinical Medicine, 2022, v. 11, n. 10, p. 2803, doi. 10.3390/jcm11102803
- By:
- Publication type:
- Article
Strong Cellular Immune Response, but Not Humoral, against SARS-CoV-2 in Oncohematological Patients with Autologous Stem Cell Transplantation after Natural Infection.
- Published in:
- Journal of Clinical Medicine, 2022, v. 11, n. 8, p. 2137, doi. 10.3390/jcm11082137
- By:
- Publication type:
- Article
Immediate Effects of Dasatinib on the Migration and Redistribution of Naïve and Memory Lymphocytes Associated With Lymphocytosis in Chronic Myeloid Leukemia Patients.
- Published in:
- Frontiers in Pharmacology, 2019, v. 10, p. 1, doi. 10.3389/fphar.2019.01340
- By:
- Publication type:
- Article
Regular Humoral and Cellular Immune Responses in Individuals with Chronic Myeloid Leukemia Who Received a Full Vaccination Schedule against COVID-19.
- Published in:
- Cancers, 2023, v. 15, n. 20, p. 5066, doi. 10.3390/cancers15205066
- By:
- Publication type:
- Article
Persistent Immunity against SARS-CoV-2 in Individuals with Oncohematological Diseases Who Underwent Autologous or Allogeneic Stem Cell Transplantation after Vaccination.
- Published in:
- Cancers, 2023, v. 15, n. 8, p. 2344, doi. 10.3390/cancers15082344
- By:
- Publication type:
- Article
Strong Humoral but Not Cellular Immune Responses against SARS-CoV-2 in Individuals with Oncohematological Disease Who Were Treated with Rituximab before Receiving a Vaccine Booster.
- Published in:
- Cancers, 2022, v. 14, n. 22, p. 5537, doi. 10.3390/cancers14225537
- By:
- Publication type:
- Article
Switching to second-generation tyrosine kinase inhibitor improves the response and outcome of frontline imatinib-treated patients with chronic myeloid leukemia with more than 10% of BCR-ABL/ABL ratio at 3 months.
- Published in:
- Cancer Medicine, 2015, v. 4, n. 7, p. 995, doi. 10.1002/cam4.440
- By:
- Publication type:
- Article
Predictive factors for anemia response to erythropoiesis-stimulating agents in myelofibrosis.
- Published in:
- European Journal of Haematology, 2017, v. 98, n. 4, p. 407, doi. 10.1111/ejh.12846
- By:
- Publication type:
- Article
Critical review of clinical data and expert-based recommendations for the use of bosutinib in the treatment of chronic myeloid leukemia.
- Published in:
- Frontiers in Oncology, 2024, p. 1, doi. 10.3389/fonc.2024.1405467
- By:
- Publication type:
- Article
Impaired Antibody-Dependent Cellular Cytotoxicity in a Spanish Cohort of Patients With COVID-19 Admitted to the ICU.
- Published in:
- Frontiers in Immunology, 2021, v. 12, p. 1, doi. 10.3389/fimmu.2021.742631
- By:
- Publication type:
- Article
Impaired Cytotoxic Response in PBMCs From Patients With COVID-19 Admitted to the ICU: Biomarkers to Predict Disease Severity.
- Published in:
- Frontiers in Immunology, 2021, v. 12, p. 1, doi. 10.3389/fimmu.2021.665329
- By:
- Publication type:
- Article
DASFREE: Treatment-Free Remission (TFR) After Discontinuation of Dasatinib in Patients with Chronic Myeloid Leukemia in Chronic Phase (CML-CP) and Deep Molecular Response (DMR).
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2019, v. 19, p. S299, doi. 10.1016/j.clml.2019.07.253
- By:
- Publication type:
- Article
Treatment-Free Remission (TFR) in Patients with Chronic-Phase Chronic Myeloid Leukemia (CML-CP) and Stable Deep Molecular Response (DMR) Discontinuing Dasatinib (DASFREE).
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2018, v. 18, p. S220, doi. 10.1016/j.clml.2018.07.090
- By:
- Publication type:
- Article
Tyrosine Kinase Inhibitors Available for Chronic Myeloid Leukemia: Efficacy and Safety.
- Published in:
- Frontiers in Oncology, 2019, p. 1, doi. 10.3389/fonc.2019.00603
- By:
- Publication type:
- Article
Safety profile of bosutinib in Japanese versus non-Japanese patients with chronic myeloid leukemia: a pooled analysis.
- Published in:
- International Journal of Hematology, 2022, v. 115, n. 6, p. 838, doi. 10.1007/s12185-022-03314-y
- By:
- Publication type:
- Article
Patients with secondary acute myeloid leukemia undergoing allogeneic stem‐cell transplant have inferior outcomes than de novo acute myeloid leukemia regardless minimal residual disease level by flow cytometry.
- Published in:
- Hematological Oncology, 2023, v. 41, n. 4, p. 753, doi. 10.1002/hon.3160
- By:
- Publication type:
- Article
Bosutinib shows low cross intolerance, in chronic myeloid leukemia patients treated in fourth line. Results of the Spanish compassionate use program.
- Published in:
- American Journal of Hematology, 2015, v. 90, n. 5, p. 429, doi. 10.1002/ajh.23973
- By:
- Publication type:
- Article
LONG-TERM PROTECTION OF CD4+ T CELLS AGAINST HIV BY ONE-YEAR TREATMENT WITH PONATINIB.
- Published in:
- Topics in Antiviral Medicine, 2023, v. 31, n. 2, p. 170
- By:
- Publication type:
- Article
ONE-YEAR TREATMENT WITH PONATINIB INDUCES SUSTAINED CYTOTOXIC ACTIVITY AGAINST HIV.
- Published in:
- Topics in Antiviral Medicine, 2023, v. 31, n. 2, p. 128
- By:
- Publication type:
- Article
Association between HLA-C alleles and COVID-19 severity in a pilot study with a Spanish Mediterranean Caucasian cohort.
- Published in:
- PLoS ONE, 2022, v. 17, n. 8, p. 1, doi. 10.1371/journal.pone.0272867
- By:
- Publication type:
- Article
Different polarization and functionality of CD4+ T helper subsets in people with post-COVID condition.
- Published in:
- Frontiers in Immunology, 2024, p. 01, doi. 10.3389/fimmu.2024.1431411
- By:
- Publication type:
- Article
Real‐world analysis of main clinical outcomes in patients with polycythemia vera treated with ruxolitinib or best available therapy after developing resistance/intolerance to hydroxyurea.
- Published in:
- Cancer (0008543X), 2022, v. 128, n. 13, p. 2441, doi. 10.1002/cncr.34195
- By:
- Publication type:
- Article
Janus kinase inhibitor ruxolitinib in combination with nilotinib and prednisone in patients with myelofibrosis (RuNiC study): A phase Ib, multicenter study.
- Published in:
- EJHaem, 2023, v. 4, n. 2, p. 401, doi. 10.1002/jha2.685
- By:
- Publication type:
- Article
Sustained antiviral response against in vitro HIV-1 infection in peripheral blood mononuclear cells from people with chronic myeloid leukemia treated with ponatinib.
- Published in:
- Frontiers in Pharmacology, 2024, p. 1, doi. 10.3389/fphar.2024.1426974
- By:
- Publication type:
- Article
A BCR-ABL1 cutoff of 1.5% at 3 months, determined by the GeneXpert system, predicts an optimal response in patients with chronic myeloid leukemia.
- Published in:
- PLoS ONE, 2017, v. 12, n. 3, p. 1, doi. 10.1371/journal.pone.0173532
- By:
- Publication type:
- Article